BR112021021106A2 - Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona - Google Patents
Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'onaInfo
- Publication number
- BR112021021106A2 BR112021021106A2 BR112021021106A BR112021021106A BR112021021106A2 BR 112021021106 A2 BR112021021106 A2 BR 112021021106A2 BR 112021021106 A BR112021021106 A BR 112021021106A BR 112021021106 A BR112021021106 A BR 112021021106A BR 112021021106 A2 BR112021021106 A2 BR 112021021106A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- fumarate
- plk4
- methoxyspiro
- dimethylmorpholino
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title abstract 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract 3
- 101150005816 PLK4 gene Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona. a presente invenção refere-se a um sal de fumarato de forma cristalina s4 de um composto (i) representado pela seguinte fórmula estrutural; a razão molar entre o composto (i) e ácido fumárico é de 1,0:1:0. a forma cristalina s4 caracterizada por um padrão de difração de raios x (método) do pó que compreende picos em 6,6o, 9,8o, 16,3o, 21,1o, 28,7o e 30,2o ± 0,2 em 2o. .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837858P | 2019-04-24 | 2019-04-24 | |
| PCT/CA2020/050535 WO2020215155A1 (en) | 2019-04-24 | 2020-04-23 | Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021106A2 true BR112021021106A2 (pt) | 2021-12-14 |
Family
ID=72940551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021106A BR112021021106A2 (pt) | 2019-04-24 | 2020-04-23 | Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220204494A1 (pt) |
| EP (1) | EP3959209A4 (pt) |
| JP (1) | JP2022530028A (pt) |
| KR (1) | KR20220004102A (pt) |
| CN (1) | CN113966330A (pt) |
| AU (1) | AU2020264143A1 (pt) |
| BR (1) | BR112021021106A2 (pt) |
| CA (1) | CA3137191A1 (pt) |
| EA (1) | EA202192903A1 (pt) |
| IL (1) | IL287394A (pt) |
| MA (1) | MA55767A (pt) |
| MX (1) | MX2021012993A (pt) |
| SG (1) | SG11202111003UA (pt) |
| TW (1) | TW202104216A (pt) |
| WO (1) | WO2020215155A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308346A (en) | 2021-05-11 | 2024-01-01 | Oric Pharmaceuticals Inc | POLO-like kinase 4 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2756568C (en) | 2009-04-06 | 2018-02-13 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| CN102892766B (zh) | 2010-04-06 | 2015-05-20 | 大学健康网络 | 激酶抑制剂和用其治疗癌症的方法 |
| HUE043194T2 (hu) * | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
-
2020
- 2020-04-23 BR BR112021021106A patent/BR112021021106A2/pt unknown
- 2020-04-23 MX MX2021012993A patent/MX2021012993A/es unknown
- 2020-04-23 CN CN202080030678.8A patent/CN113966330A/zh active Pending
- 2020-04-23 AU AU2020264143A patent/AU2020264143A1/en active Pending
- 2020-04-23 EP EP20795605.3A patent/EP3959209A4/en active Pending
- 2020-04-23 WO PCT/CA2020/050535 patent/WO2020215155A1/en unknown
- 2020-04-23 KR KR1020217037777A patent/KR20220004102A/ko unknown
- 2020-04-23 MA MA055767A patent/MA55767A/fr unknown
- 2020-04-23 EA EA202192903A patent/EA202192903A1/ru unknown
- 2020-04-23 SG SG11202111003UA patent/SG11202111003UA/en unknown
- 2020-04-23 CA CA3137191A patent/CA3137191A1/en active Pending
- 2020-04-23 JP JP2021562948A patent/JP2022530028A/ja active Pending
- 2020-04-23 US US17/605,108 patent/US20220204494A1/en active Pending
- 2020-04-23 TW TW109113591A patent/TW202104216A/zh unknown
-
2021
- 2021-10-19 IL IL287394A patent/IL287394A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3137191A1 (en) | 2020-10-29 |
| KR20220004102A (ko) | 2022-01-11 |
| WO2020215155A8 (en) | 2020-11-26 |
| JP2022530028A (ja) | 2022-06-27 |
| CN113966330A (zh) | 2022-01-21 |
| WO2020215155A1 (en) | 2020-10-29 |
| TW202104216A (zh) | 2021-02-01 |
| MX2021012993A (es) | 2021-12-10 |
| EA202192903A1 (ru) | 2022-02-09 |
| MA55767A (fr) | 2022-03-02 |
| AU2020264143A1 (en) | 2021-10-28 |
| EP3959209A4 (en) | 2022-12-28 |
| US20220204494A1 (en) | 2022-06-30 |
| EP3959209A1 (en) | 2022-03-02 |
| IL287394A (en) | 2021-12-01 |
| SG11202111003UA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| UY31083A1 (es) | Derivados de sulfoximinas para la inhibicion de b-secretasa | |
| BR112015006075A2 (pt) | composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina | |
| CY1118107T1 (el) | Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr | |
| ATE475415T1 (de) | Neue salze des wirkstoffs rasagilin | |
| KR950700258A (ko) | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체(heterocyclic carbonic acid derivatives which bind to retinoid receptors(rar)) | |
| IL167168A (en) | Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria | |
| PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| BR112015022077A2 (pt) | composto de pirazol-amida e usos medicinais do mesmo | |
| MD4489C1 (ro) | Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină | |
| BR112013006594A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto | |
| BR0111750A (pt) | Método para melhorar a atividade de um sal de alumìnio ou um sal de alumìnio/zircÈnio, sal melhorado obtido pelo mesmo, e, produto antiperspirante e/ou desodorante anidro produzido com um sal melhorado | |
| BRPI0507334A (pt) | processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina | |
| PL2185510T3 (pl) | Nowe sole bazedoksyfenu | |
| BR112021021106A2 (pt) | Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona | |
| BR112014031616A2 (pt) | compostos de fenoxietil piperidina | |
| MX2020009612A (es) | Polimorfos de sal de calcio novedosos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. | |
| SV2010003770A (es) | Composicion y proceso- 356 | |
| MY163501A (en) | Anti-biofilm carbonate compouns for use in oral care compositions | |
| BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
| BR112012027387A2 (pt) | composição para controle de doenças de plantas e uso da mesma | |
| IN2015DN00837A (pt) | ||
| BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
| MY147951A (en) | Crystalline potassium salt of lipoxin a? analogs |